Na Wu1, Xinghua Chen2, Tongjian Cai1, Long Wu1, Ying Xiang1, Mengxuan Zhang1, Yafei Li1, Zhiyuan Song2, Li Zhong3. 1. Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing, People's Republic of China; Evidence-based Medicine and Clinical Epidemiology Center, Third Military Medical University, Chongqing, People's Republic of China. 2. Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, People's Republic of China. 3. Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, People's Republic of China. Electronic address: zhongli28@hotmail.com.
Abstract
BACKGROUND: Atrial fibrillation (AF) increases the risk of stroke and thromboembolic events. Recently, biomarkers have been proposed as a practical tool to predict adverse outcomes in patients with AF. The prognostic value of inflammatory and hemostatic markers in AF has been widely studied; however, the results of previous studies have been inconclusive. METHODS: We conducted a systematic review and meta-analysis to evaluate the association of inflammatory and hemostatic markers with stroke and thromboembolic events in patients with AF. RESULTS: A total of 27 studies including 22,176 participants met our inclusion criteria for the systematic review. Our meta-analysis determined that elevated circulating plasminogen activator inhibitor-1 (PAI-1) and thrombin-antithrombin (TAT) were significantly associated with increased risk of stroke in patients with AF (standardized mean difference [SMD], 0.89; 95% confidence interval [CI], 0.20-1.59 and 1.43; 95% CI, 0.40-2.47, respectively). Higher levels of D-dimer were associated with increased subsequent thromboembolic event risk with a pooled hazard ratio of 2.90 (95% CI, 1.22-6.90) for cohort studies and an SMD of 0.93 (95% CI, 0.36-1.50) for case-control studies. There was also very limited evidence indicating that other biomarkers-such as interleukin-6, von Willebrand factor, P-selectin, and mean platelet volume-could predict adverse outcomes in AF. CONCLUSIONS: In conclusion, increased circulating PAI-1 and TAT levels were significantly associated with subsequent stroke in patients with AF, and high levels of D-dimer were associated with thromboembolic events in AF. Further epidemiologic studies are needed to accumulate more evidence on the prognostic role of inflammatory and hemostatic markers in AF.
BACKGROUND:Atrial fibrillation (AF) increases the risk of stroke and thromboembolic events. Recently, biomarkers have been proposed as a practical tool to predict adverse outcomes in patients with AF. The prognostic value of inflammatory and hemostatic markers in AF has been widely studied; however, the results of previous studies have been inconclusive. METHODS: We conducted a systematic review and meta-analysis to evaluate the association of inflammatory and hemostatic markers with stroke and thromboembolic events in patients with AF. RESULTS: A total of 27 studies including 22,176 participants met our inclusion criteria for the systematic review. Our meta-analysis determined that elevated circulating plasminogen activator inhibitor-1 (PAI-1) and thrombin-antithrombin (TAT) were significantly associated with increased risk of stroke in patients with AF (standardized mean difference [SMD], 0.89; 95% confidence interval [CI], 0.20-1.59 and 1.43; 95% CI, 0.40-2.47, respectively). Higher levels of D-dimer were associated with increased subsequent thromboembolic event risk with a pooled hazard ratio of 2.90 (95% CI, 1.22-6.90) for cohort studies and an SMD of 0.93 (95% CI, 0.36-1.50) for case-control studies. There was also very limited evidence indicating that other biomarkers-such as interleukin-6, von Willebrand factor, P-selectin, and mean platelet volume-could predict adverse outcomes in AF. CONCLUSIONS: In conclusion, increased circulating PAI-1 and TAT levels were significantly associated with subsequent stroke in patients with AF, and high levels of D-dimer were associated with thromboembolic events in AF. Further epidemiologic studies are needed to accumulate more evidence on the prognostic role of inflammatory and hemostatic markers in AF.
Authors: Gro Grimnes; Lars D Horvei; Vladimir Tichelaar; Sigrid K Brækkan; John-Bjarne Hansen Journal: Haematologica Date: 2016-06-13 Impact factor: 9.941
Authors: Barbara Ratajczak-Tretel; Anna Tancin Lambert; Henriette Johansen; Bente Halvorsen; Vigdis Bjerkeli; David Russell; Else Charlotte Sandset; Hege Ihle-Hansen; Erik Eriksen; Halvor Næss; Vojtech Novotny; Andrej Netland Khanevski; Thomas C Truelsen; Titto Idicula; Karen L Ægidius; Håkon Tobro; Siv B Krogseth; Håkon Ihle-Hansen; Guri Hagberg; Christina Kruuse; Kathrine Arntzen; Grete K Bakkejord; Maja Villseth; Ingvild Nakstad; Guttorm Eldøen; Raheel Shafiq; Anne Gulsvik; Martin Kurz; Mehdi Rezai; Jesper Sømark; Stein-Helge Tingvoll; Christine Jonassen; Susanne Ingebrigtsen; Linn Hofsøy Steffensen; Christine Kremer; Dan Atar; Anne Hege Aamodt Journal: Eur Stroke J Date: 2019-03-19
Authors: José Miguel Rivera-Caravaca; Vanessa Roldán; María Asunción Esteve-Pastor; Mariano Valdés; Vicente Vicente; Gregory Y H Lip; Francisco Marín Journal: J Am Heart Assoc Date: 2017-07-20 Impact factor: 5.501